Trial · NCT03440385
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 | Week 12 | Intent to Treat population included all the randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission | Week 12 | Intent to Treat Population included all the randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% | Week 12 | Intent to Treat population included all the randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Reduction From Baseline in the Crohn's Disease Activity Index (CDAI) Score of >= 100 Points or a Total CDAI Score < 150 | Week 12 | Intent to treat population included all the randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 and SES-CD Decrease From Baseline of ≥ 50% | Week 12 | Intent to Treat population included all the randomized participants. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 and Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% | Week 12 | Intent to Treat population included all the randomized participants. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission and a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score <= 4 Points and Decrease >= 2 Points | Week 12 | Intent to Treat population included all the randomized subjects. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Global Histologic Activity Score (GHAS) Remission | Week 12 | Intent to treat population included all the randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With CDAI Reduction From Baseline of >=70 Points | Week 12 | Intent to treat population included all the randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Absence of Ulcers ≥ 0.5 cm With no Segment With Any Ulcerated Surface ≥10% | Week 12 | Intent to treat participants included all the randomized participants. | percentage of partiicpants | NUMBER |
| SECONDARY | Percentage of Participants With a Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of ≥ 50% | Week 12 | Intent to Treat included all the randomized participants. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Abdominal Pain (AP) and Stool Frequency (SF) Clinical Remission and an Endoscopic (50%) Response | Week 12 | Intent to Treat population included all the randomized participants. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration. | percentage of particpants | NUMBER |
| SECONDARY | Percentage of Participants With Robarts Histologic Index (RHI) Mucosal Healing at Week 12 | Week 12 | Intent-to-treat population included all the randomized participants. Baseline was defined as the last assessment prior to the start time of the first drug administration if time of measurement is available else the last assessment prior to or on the date of the first drug administration. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03440385/outcomes